Answers are grounded in this paper and cite their sources.
Clinical case illustrates structural changes in gastric mucosa due to chronic autoimmune atrophic gastritis, highlighting the impact of alpha-glutamyl-tryptophan therapy.
Chronic autoimmune atrophic gastritis is one of the key risk factors for the development of gastric malignancies. Objective: To describe a clinical case illustrating the dynamics of long-term structural changes in the gastric mucosa in the absence of treatment and following therapy with alpha-glutamyl-tryptophan. Clinical case. A chronological account is presented detailing the diagnosis, treatment, clinical features, and histological findings from gastric mucosal biopsies in a 57-year-old patient, monitored from 2020 to 2025. Conclusion. This clinical case demonstrates the potential of alpha-glutamyl-tryptophan as a course-based therapy for the early and timely management of structural changes in the gastric mucosa associated with chronic autoimmune atrophic gastritis.
No takes yet. Share an insight, caveat, or question.
Tryapitsyn et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: